Holen Sie sich die Stockscreener-App
0.4819
5.52%
0.0252
Handel nachbörslich:
.47
-0.0119
-2.47%
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Dimensional Fund Advisors LP Sells 86,264 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com India
BioAtla receives Nasdaq delisting warning - Investing.com Australia
BioAtla Receives Nasdaq Non-Compliance Notice - TipRanks
HC Wainwright Issues Negative Estimate for BioAtla Earnings - Defense World
HC Wainwright Predicts BioAtla’s Q1 Earnings (NASDAQ:BCAB) - Defense World
BioAtla Inc (NASDAQ: BCAB): Is Its Value Too High Compared To Others? - Stocksregister
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
BioAtla stock holds $1 target, JMP affirms Market Outperform By Investing.com - Investing.com Nigeria
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus By Investing.com - Investing.com India
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus - Investing.com Australia
Bioatla Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gaining Ground: BioAtla Inc (BCAB) Closes Lower at 0.48, Down -8.19 - DWinneX
BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Call Transcript - Insider Monkey
BioAtla Q1 2025 Earnings Call Transcript - MarketBeat
BioAtla (NASDAQ:BCAB) vs. Novavax (NASDAQ:NVAX) Head-To-Head Comparison - Defense World
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
Bioatla, Inc. Earnings Call Highlights Clinical Success - TipRanks
BioAtla, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations - Investing.com
BioAtla, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCAB) - Seeking Alpha
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Re - GuruFocus
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations By Investing.com - Investing.com UK
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Results | BCAB Stock News - GuruFocus
BioAtla reports Q1 EPS (26c), consensus (29c) - TipRanks
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla Reports Breakthrough: Cancer Drug Triples Survival Rate vs Standard Treatment in Lung Cancer Study - Stock Titan
BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC - Defense World
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - Sete News
BioAtla Inc (BCAB) shows promising results - uspostnews.com
BioAtla Reveals Next-Gen Cancer Treatment Progress: Key Updates Coming at Citizens Conference - Stock Titan
BCAB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
An Analysis of BioAtla Inc (BCAB)’s Potential Price Growth - knoxdaily.com
BioAtla to Participate in the Citizens Life Sciences Conference - TradingView
BioAtla Q1 2025 Earnings: Biotech Leader to Share Latest Cancer Treatment Progress on May 6 - Stock Titan
Bank of Montreal Can Sells 522,252 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister
BioAtla announces poster presentations at 2025 AACR meeting - TipRanks
How did BioAtla Inc (BCAB) fare last session? - uspostnews.com
BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):